悦康药业：上半年研发投入营收占比同比增加7.54个百分点

Core Insights - The company reported a revenue of 1.17 billion yuan for the first half of 2025, with R&D investment amounting to 209 million yuan, representing 17.91% of revenue, an increase of 7.54 percentage points year-on-year [1] - The company has established eleven core technology platforms focusing on various drug types, including nucleic acid drugs and high-end traditional Chinese medicine, and has a pipeline of over twenty key projects [1] - As of June 30, 2025, the company has 42 R&D projects, including 21 innovative drugs and 21 generic drugs, and has accumulated 349 patents, with 21 new applications and 32 new patents granted in the first half of 2025 [1] R&D Progress - The company made significant advancements in key innovative drugs, with several products in the NDA review stage, including traditional Chinese medicine injections and other innovative formulations [2] - The company has successfully launched its small nucleic acid drug and mRNA vaccine R&D and pilot production platforms, which are now operating efficiently [2] - The company aims to focus on three major therapeutic areas: cardiovascular diseases, tumors, and infectious diseases, while continuing to develop a diverse pipeline through various methods such as independent R&D and collaborations [2]